Letter From the Chair

HomeNews ▶ Letter From the Chair
Letter From the Chair

Dean E. Schraufnagel

Dean E. Schraufnagel, MD

Dear Colleagues and Friends,

I have good news to report.

We recently surveyed the 235 researchers who received $17.6 million from the ATS Foundation since it began and found that they have gone on to receive $268 million in federal funding—that’s a return on investment of $15 per dollar awarded.

Our efforts to expand the Research Program recently got an important boost with the addition of five new members to our board. Four of these trustees are from industry: Stuart Loesch, of ALK; Chris Blango, of AstraZeneca; Julie Vu, PharmD, of Genentech; and Greg Lund, of the Lund Research Group. Jeffrey Goldstein, a lung transplant patient, CEO of the Lung Transplant Foundation, and generous donor to the ATS Foundation, also joined the board.

With these new members, the board better represents the range of stakeholders needed to find cures or better treatments for respiratory disease, critical care illnesses, and sleep disorders and will help us attract more resources for promising researchers, here in the U.S. and internationally.

I am also happy to report that our 10th annual benefit held during ATS 2018 raised nearly a half-million dollars and that we recently awarded our first nursing research grant to Jennifer Seaman, PhD, RN. You can read more about her ICU research project, and the generous donor who made the grant possible, in this Bulletin.

I could go on, but I think my point is clear: the ATS Foundation is a growing source of hope for respiratory patients, and your support has made that possible. Thank you!

Dean E. Schraufnagel, MD

ATS Foundation Chair

Read about Research Program awardee Jennifer Seaman, PhD, RN; the Research Program Benefit; the 2018 Ziskind Awardees; and more in the Foundation Bulletin.

The ATS supports the ATS Foundation’s administrative expenses, assuring that every dollar contributed goes directly to support programs.